Disease · MONDO_0005799
hookworm infectious disease
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. hookworm infectious disease. Diseases, record MONDO_0005799. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005799
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- hookworm infectious disease
- Open Targets ID
- MONDO_0005799
- Other names
- Hookworm Infections, ancylostomiasis and necatoriasis
- Highest stage of its drugs
- Phase 3, for 4 of its 6 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs6
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ALBENDAZOLE | CHEMBL1483 | Small molecule | Phase 3 | ClinicalTrials.gov | 10 | 10 | 10 | Drugs and targets |
| IVERMECTIN | CHEMBL6067487 | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets | |
| MEBENDAZOLE | CHEMBL685 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| EMODEPSIDE | CHEMBL2104404 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| MOXIDECTIN | CHEMBL2104415 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ALUMINUM HYDROXIDE | CHEMBL1200706 | Small molecule | Phase 2 | TTD | 1 | 0 | 0 | Drugs and targets |
Targets0
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
None in this release.
Trials15
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03527732 | Efficacy and Safety of IVM/ALB Co-administration | Phase 2/3 | 1,673 | 2024-03-20 | Trichuriasis | ALBENDAZOLE, IVERMECTIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03527745 | Albendazole Dose Finding and Pharmacokinetics in Children and Adults | Phase 2 | 700 | 2021-01-06 | Trichuriasis, Hookworm Infections | ALBENDAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT04700423 | Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration | Phase 2/3 | 536 | 2024-12-05 | Trichuriasis, Ascariasis, Hookworm Infections, Helminthes; Infestation, Intestinal | ALBENDAZOLE, IVERMECTIN, MOXIDECTIN | Its record names the disease | ClinicalTrials.gov |
| NCT03995680 | Efficacy and Safety of a New Chewable Versus the Swallowable Tablet of Mebendazole Against Hookworm | Phase 2 | 397 | 2020-07-20 | Hookworm Infections | MEBENDAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT01350271 | Comparative Efficacy of Different Mebendazole Polymorphs in the Treatment of Soil-transmitted Helminth Infections | Phase 3 | 214 | 2013-04-22 | Necator Americanus Infection | MEBENDAZOLE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04177654 | Monitoring Drug Efficacy and Anthelmintic Resistance in Soil-transmitted Helminth Programs | 9,457 | Soil-transmitted Helminth Infections | ALBENDAZOLE, MEBENDAZOLE | Open Targets' reading of its record | ClinicalTrials.gov | ||
| NCT02420574 | Assessment of Drug Efficacy of Local Albendazole | Not applicable | 679 | Helminthiasis | ALBENDAZOLE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00207753 | Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections | Not applicable | 550 | Ascariasis, Trichuriasis, Hookworm Infection, Strongyloidiasis, Pediculosis | ALBENDAZOLE, IVERMECTIN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT05538767 | Efficacy and Safety of Emodepside in Adolescents and Adults Infected With Hookworm | Phase 2 | 320 | Hookworm Infections | EMODEPSIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT06736691 | Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections | Phase 3 | 315 | Trichuris Trichiura; Infection, Hookworm Infection, Ascaris Lumbricoides Infection | EMODEPSIDE, MEBENDAZOLE | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 15
See all 15 trialsComparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Chewable Tablet of Mebendazole vs Swallowable Tablet of Mebendazole: deaths from any cause | 0 of 197 | 0 of 196 | 393 | NCT03995680 | Trial comparisons |
| Chewable Tablet of Mebendazole vs Swallowable Tablet of Mebendazole: serious adverse events | 0 of 197 | 0 of 196 | 393 | NCT03995680 | Trial comparisons |
Papers from its trials35
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005799
GET https://conductscience.org/api/diseases/v1/MONDO_0005799/papers?page=2